Receptor tyrosine kinase/growth factor signaling
Receptor tyrosine kinase cell signaling pathways regulate a variety of cellular processes including cell growth, proliferation, differentiation, survival, gene transcription, metabolic regulation, and others. Receptor tyrosine kinase signaling pathways are activated by the binding of a ligand, such as a growth factor, to the receptor tyrosine kinase. Receptor tyrosine kinase signaling pathways are inhibited by complex negative feedback loops which function to attenuate the activated receptor signaling. 
Figure 1. Binding of a growth factor (e.g., EGF, HGF) to a receptor tyrosine kinase activates the receptor tyrosine kinase and typically causes the dimerization of the two receptor monomers. The receptors are activated by phosphorylation within their kinase domains. Once the receptor is turned on, numerous downstream pathways are activated including MAP kinase signaling, JAK/STAT signaling, and PI3K/AKT1/MTOR signaling. Specific nodes in the pathway that are therapeutically actionable are noted.
ERBB2, EGFR, KIT, ALK, and MET are the most frequent biomarkers that serve as inclusion criteria in therapies targeting the receptor tyrosine kinase/growth factor signaling pathway.
Biomarkers in the receptor tyrosine kinase/growth factor signaling pathway serve as inclusion eligibility criteria in 1884 clinical trials, of which 1456 are open and 428 are closed. The genes ERBB2, EGFR, ALK, FLT3, and ROS1 on this pathway most frequently harbor alterations that are inclusion eligibility criteria for clinical trials.
Of the trials that contain alteration(s) in the receptor tyrosine kinase/growth factor signaling pathway as inclusion criteria, 30 are early phase 1 (25 open), 43 are n/a (36 open), 480 are phase 1 (331 open), 290 are phase 1/phase 2 (230 open), 781 are phase 2 (614 open), 31 are phase 2/phase 3 (25 open), 210 are phase 3 (183 open), and 10 are phase 4 (5 open) .